Year: 2010
Type: article
Abstract: The world is facing an epidemic of chronic kidney disease (CKD) and in South Africa, death rates from end-stage renal disease (ESRD) have risen by 68% from 1999 to 2006.1 The major drivers of this epidemic are type 2 diabetes (T2D) and/or hypertension.2 All major guidelines recommend ACE inhibitors (ACEIs) or angiotensin receptor blockers (ARBs) for the prevention of CKD.3-5 Recently, two important studies have reported no benefit on renal outcome in patients at high cardiovascular risk or in patients with type 1 diabetes receiving renin–angiotensin system (RAS) inhibitors,6,7 and commentators have questioned the validity of the guideline recommendations.8,9
To improve our interpretation of studies of renal disease there needs to be a better understanding of renal physiology and ‘hard’ renal versus surrogate endpoints.
Source: PubMed Central
Author: Brian Rayner
Language: English
Subfield: Nephrology
Field: Medicine
Domain: Health Sciences
Open Access status: green
OpenAlex ID: W2267906939